ArticleFrontiers in immunology2017
Absence of the Non-Signalling Chemerin Receptor CCRL2 Exacerbates Acute Inflammatory Responses
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Novel Adipokines in Critical Illness and Sepsis: Chemerin, Vaspin, and Omentin-1: A Comprehensive Evidence-Based Review.Biomedicines · 2026Review
- The Role of Chemerin in Neutrophil Activation and Diseases of the Lung.Biomedicines · 2025Review
- Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model.Frontiers in immunology · 2025Article
- Ly6CCells · 2024Article
- Transcriptomic and intervention evidence reveals domestic dogs as a promising model for anti-inflammatory investigation.Aging cell · 2024Article
- Dual-omics reveals temporal differences in acute sympathetic stress-induced cardiac inflammation following αActa pharmacologica Sinica · 2023Article
- Article
- Megakaryocyte NLRP3 hyperactivation induces mild anemia and potentiates inflammatory response in mice.Frontiers in immunology · 2023Article
- Bruton's TK regulates myeloid cell recruitment during acute inflammation.British journal of pharmacology · 2022Article
- Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner.Oncogene · 2022Article
- The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.Science advances · 2022Article
- Digital Cell Atlas of Mouse Uterus: From Regenerative Stage to Maturational Stage.Frontiers in genetics · 2022Article
- Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning.American journal of respiratory and critical care medicine · 2021Article
- The complex role of adipokines in obesity, inflammation, and autoimmunity.Clinical science (London, England : 1979) · 2021Review
- Molecular Basis for CCRL2 Regulation of Leukocyte Migration.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Chemerin is a chemotactic protein that induces migration of several immune cells including macrophages, immature dendritic cells, and NK cells. Chemerin binds to three G protein-coupled receptors (GPCRs), including CCRL2. The exact function of CCRL2 remains unclear. CCRL2 expression is rapidly upregulated during inflammation, but it lacks the intracellular DRYLAIV motif required for classical GPCR downstream signalling pathways, and it has not been reported to internalise chemerin upon binding. The aim of this study was to investigate what role if any CCRL2 plays during acute inflammation. Using the zymosan- and thioglycollate-induced murine models of acute inflammation, we report that mice deficient in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.